1. Home
  2. MDB vs NTRA Comparison

MDB vs NTRA Comparison

Compare MDB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MongoDB Inc.

MDB

MongoDB Inc.

HOLD

Current Price

$341.10

Market Cap

30.0B

Sector

Technology

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$213.39

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDB
NTRA
Founded
2007
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.0B
32.9B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
MDB
NTRA
Price
$341.10
$213.39
Analyst Decision
Buy
Strong Buy
Analyst Count
35
14
Target Price
$420.91
$253.79
AVG Volume (30 Days)
1.4M
947.4K
Earning Date
03-01-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
30.24
59.52
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$22.41
$34.18
Revenue Next Year
$18.77
$16.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$140.94
$125.38
52 Week High
$444.72
$256.36

Technical Indicators

Market Signals
Indicator
MDB
NTRA
Relative Strength Index (RSI) 44.36 45.24
Support Level $340.40 $204.04
Resistance Level $366.53 $220.65
Average True Range (ATR) 21.63 9.15
MACD 0.90 0.41
Stochastic Oscillator 54.70 49.48

Price Performance

Historical Comparison
MDB
NTRA

About MDB MongoDB Inc.

Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: